Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q40581940)
Watch
English
Bevacizumab improves quality of life in patients with recurrent glioblastoma.
scientific article published on 2 October 2011
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
title
Bevacizumab improves quality of life in patients with recurrent glioblastoma
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
main subject
bevacizumab
1 reference
based on heuristic
inferred from title
author
Seema Nagpal
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
author name string
Griffith Harsh
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
Lawrence Recht
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
2 October 2011
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
published in
Chemotherapy Research and Practice
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
volume
2011
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
page(s)
602812
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
copyright license
Creative Commons Attribution 3.0 Unported
start time
2 October 2011
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
1 reference
stated in
April 2022 Public Data File from Crossref
cites work
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
22 September 2017
Use of dexamethasone in treatment of cerebral edema associated with brain tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
17 June 2018
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Bevacizumab and recurrent malignant gliomas: a European perspective
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Translating biological insights into clinical endpoints in neuro-oncology
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective cohort
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Response criteria for phase II studies of supratentorial malignant glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263615
retrieved
20 August 2018
Identifiers
DOI
10.1155/2011/602812
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
PMC publication ID
3263615
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
PubMed publication ID
22312554
1 reference
stated in
Europe PubMed Central
PMC publication ID
3263615
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22312554%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
ResearchGate publication ID
221812883
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit